ZellNet will be a distributor for MedGenome’s OncoPept™ – a powerful end to end genomics platform to accelerate immune-oncology research.
FOSTER CITY, CA, UNITED STATES, June 4, 2016 /EINPresswire.com/ — MedGenome announced a strategic partnership with ZellNet Consulting – a trusted provider of immune monitoring services for over 18 years.
This arrangement seamlessly integrates MedGenome’s cancer immunotherapy genomics platform with ZellNet’s immune monitoring services. This partnership will facilitate present customers of ZellNet’s immune monitoring services to quickly expand their cancer immunotherapy research into the genomics space by leveraging the power of next-generation sequencing-based approaches of neo-antigen and neo-epitope prediction. Additionally, they will have the option to interrogate the tumor microenvironment to understand the immune cell content, cytokine network and pro-inflammatory or immune-suppressive pathways in the tumor. The OncoPept platform offered through ZellNet will enhance their current service offerings with upstream genomics to serve the customer base of both MedGenome and ZellNet.
“ZellNet is excited about the opportunity to expand its offered services with MedGenome’s cutting-edge OncoPept™ platform, a logical and timely extension” says Sylvia Janetzki, President, Zellnet Consulting “The partnership allows us to integrate important steps within the translational research and vaccine development pipeline: from what to monitor to how to monitor. Customers can continue relying on ZellNet’s superior service standards. We are proud to partner with such an exceptional company as MedGenome, and look forward to passing the advantages of this high value addition to our customers”
MedGenome is the only Next Generation Sequencing (NGS) service provider offering immune oncology researchers an enduring science-driven partnership to deliver quicker, more affordable, customized solutions to achieve superior therapeutic impact of checkpoint control inhibitors and cancer vaccines through its cancer immunotherapy genomics platform, OncoPept™.
MedGenome (http://www.medgenome.com) is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome. Its unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized health care. MedGenome is a market leader for genomic diagnostics in South Asia and a leading provider of genomics research services globally. It is also a founding member of GenomeAsia 100K initiative to sequence 100,000 genomes in South, North and East Asia.
Our NGS lab in Foster City, California is ISO 15189 compliant, CLIA certified and CAP accredited.
ZellNet Consulting (http://www.zellnet.com) is a service and consulting company specialized in functional immune monitoring techniques and their advancement. ZellNet offers a wide variety of consulting, statistical and assay evaluation services as well as seminars and workshops for Elispot and flow cytometry and their setup for immune monitoring purposes, and conducts business world-wide. ZellNet cooperates with many organizations and institutions including the CIC, C-IMT, and Elispot Resource Group to enhance the knowledge about and to improve and harmonize the performance of functional immune monitoring assay including sample handling. It is also a core member of the MIATA reporting initiative.
This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as “believe”, “estimate”, “anticipate”, “plan”, “predict”, “may”, “hope”, “can”, “will”, “should”, “expect”, “intend”, “is designed to”, “with the intent”, “potential”, the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements speak only as of the date of this press release. The events and circumstances reflected in MedGenome’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
email us here